Britain's drugs cost-effectiveness watchdog NICE said on Thursday it will recommend Eli Lilly's obesity drug Mounjaro be made available to around 220,000 people in the country via the state health ...

The U.K. will soon offer Eli Lilly's Mounjaro for people with obesity — but only to a small share of those medically eligible ...

Those treated with tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 receptor agonist, lost on ...

In a press release, Lilly announced that in its latest trial comparing its medication, Zepbound, to Wegovy, made by Novo ...

Eli Lilly said on Wednesday patients taking its obesity drug Zepbound lost 47% more weight than those who were given Novo ...

Eli Lilly’s weight loss drug, Zepbound, has been shown to lead to more significant weight loss than Novo Nordisk’s Wegovy, ...

Adults taking Zepbound lost 47% more weight on average than those taking Wegovy, according to clinical trial data from ...

One of Eli Lilly's potential competitors in the weight loss market just reported unimpressive trial results. The company ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

The price of Wegovy, the diabetes control drug's glamorous anti-obesity sibling, may also be falling, according to a Health ...

We recently compiled a list of the Billionaire Ken Fisher’s Top 15 Stock Picks Heading Into 2025. In this article, we are ...